SBFI26 as a lead inhibitor of FABP5 showed efficient anti-tumour roles in the mouse model for primary tumours implanted in the prostate gland (by 4.9- fold) and inoculated in the flank (by 52%). This evidence concerns the gene FABP5 and neoplasm.